Number of shares and voting rights of Innate Pharma as at November 1, 2019
Innate Pharma announces preclinical data presentations at SITC 2019
Innate Pharma announces closing of global offering
Innate Pharma announces the exercise in full of the option granted to the underwriters of its global offering and Nasdaq global select market listing to purchase 1,875,000 additional ADSs
Innate Pharma announces the pricing of its initial public offering on the Nasdaq global select market
Innate Pharma announces trading halt of its ordinary shares on Euronext Paris
Innate Pharma announces launch of proposed global offering and Nasdaq listing
Innate Pharma announces publication of a review article in Nature
Innate Pharma presents early clinical data on IPH5401 and monalizumab at the ESMO 2019 congress
Monalizumab to advance to Phase III in head and neck cancer
